Press release
Wet Macular Degeneration Clinical Trial Pipeline Expands as 60+ Pharma Companies Progress 75+ Novel Therapies Toward Market Entry, Finds DelveInsight | Outlook Therapeutics, Opthea, Sylentis, Boehringer Ingelheim, Molecular Partners, Sam Chun Dang Pharm,
Wet Macular Degeneration Pipeline Insights
Explore the latest breakthroughs in the Wet Macular Degeneration treatment landscape. Learn more about the evolving Wet Macular Degeneration pipeline today @ https://www.delveinsight.com/report-store/wet-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Key Takeaways from the Wet Macular Degeneration Pipeline Report
• In January 2026, Ocular Therapeutix's Phase 3 SOL-1 topline data for AXPAXLI showed superiority over Eylea in vision maintenance; company plans FDA meeting for regulatory path.
• In December 2025, FDA issued another Complete Response Letter (third) to Outlook Therapeutics for ONS-5010.
• In October 2025, 4D Molecular Therapeutics (4DMT) partnered with Otsuka Pharmaceutical: Otsuka gains exclusive rights to develop/commercialize 4D-150 (gene therapy for Wet AMD/DME) in APAC (Japan, China, etc.), with 4DMT receiving $85M upfront, up to $336M milestones, and royalties; 4DMT leads global Phase 3.
• In October 2025, Eli Lilly announced acquisition of Adverum Biotechnologies to advance Ixo-vec Phase 3 (ARTEMIS trial enrollment Q4 2025) for Wet AMD
• In September 2025, Sanofi's SAR402663, an investigational one-time intravitreal gene therapy for neovascular (Wet) AMD, received FDA Fast Track Designation.
• The leading Wet Macular Degeneration companies include Outlook Therapeutics, Opthea, Sylentis, Boehringer Ingelheim, Molecular Partners, Sam Chun Dang Pharm, Generium, Alvotech, Adverum Biotechnologies, EyePoint Pharmaceuticals, 4D Molecular Therapeutics, OliX Pharmaceuticals, Kyowa Kirin, Exonate and others.
• Promising Wet Macular Degeneration therapies include NT-101 0.05 mM, Eylea® (Aflibercept), Intravitreal aflibercept injection, RGX-314, ABP 938, Aflibercept, Ixo-vec, Ranibizumab, OPT-302, SYL1801, EYP-1901 and others.
Download for updates and the latest revolution in Wet Macular Degeneration care @ https://www.delveinsight.com/sample-request/wet-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Wet Macular Degeneration Emerging Drugs Profile
• Gene Therapies
These one-time treatments deliver genes for sustained anti-VEGF production, potentially eliminating repeated injections. ABBV-RGX-314 (REGENXBIO/AbbVie) is in Phase 3 subretinal trials (ATMOSPHERE, ASCENT), targeting regulatory submission in 2026 after strong Phase 2 data showing up to 73% injection-free at 6 months. 4D-150 (4D Molecular Therapeutics) completed Phase 3 enrollment in 4FRONT-1, with topline data in H1 2027; Phase 2 showed 77-89% injection reduction. Ixo-vec (Adverum) advances to Phase 3 ARTEMIS in 2025, with Phase 2 LUNA data indicating 88-92% burden reduction and up to 69% injection-free at 52 weeks.
• Sustained-Release Implants
Implants provide months-long drug release to ease treatment burden. DURAVYU (vorolanib, EyePoint Pharmaceuticals) entered Phase 3 (LUCIA, LUGANO) after Phase 2 DAVIO2 success, with 44% needing no rescue at 14 months; results expected 2026. AXPAXLI (axitinib, Ocular Therapeutix) reports topline from Phase 3 SOL-1 soon, targeting 6-12 month durability in treatment-naïve patients versus aflibercept. SUSVIMO (ranibizumab port, Genentech) relaunched in 2024 post-safety fixes for refillable delivery.
For more information on the Wet Macular Degeneration Emerging Drugs Profile, download DelveInsight's comprehensive Wet Macular Degeneration Pipeline Insight report @ https://www.delveinsight.com/sample-request/wet-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
The Wet Macular Degeneration Pipeline Report Provides
• Detailed insights about companies developing therapies for Wet Macular Degeneration, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Wet Macular Degeneration treatment.
• Wet Macular Degeneration companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Wet Macular Degeneration drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Wet Macular Degeneration market.
Learn more about Wet Macular Degeneration Drugs opportunities in our comprehensive Wet Macular Degeneration pipeline report @ https://www.delveinsight.com/sample-request/wet-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Wet Macular Degeneration Companies
There are 60+ key companies, such as Outlook Therapeutics, Opthea, Sylentis, Boehringer Ingelheim, Molecular Partners, Sam Chun Dang Pharm, Generium, Alvotech, Adverum Biotechnologies, EyePoint Pharmaceuticals, 4D Molecular Therapeutics, OliX Pharmaceuticals, Kyowa Kirin, Exonate and others, developing therapies for Wet Macular Degeneration.
Scope of the Wet Macular Degeneration Pipeline Report
• Coverage: Global
• Wet Macular Degeneration companies: Outlook Therapeutics, Opthea, Sylentis, Boehringer Ingelheim, Molecular Partners, Sam Chun Dang Pharm, Generium, Alvotech, Adverum Biotechnologies, EyePoint Pharmaceuticals, 4D Molecular Therapeutics, OliX Pharmaceuticals, Kyowa Kirin, Exonate and others
• Wet Macular Degeneration Therapies: NT-101 0.05 mM, Eylea® (Aflibercept), Intravitreal aflibercept injection, RGX-314, ABP 938, Aflibercept, Ixo-vec, Ranibizumab, OPT-302, SYL1801, EYP-1901 and others.
• Wet Macular Degeneration Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Wet Macular Degeneration Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
DelveInsight is a leading healthcare‐focused market research and consulting firm that provides clients with high‐quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Wet Macular Degeneration Clinical Trial Pipeline Expands as 60+ Pharma Companies Progress 75+ Novel Therapies Toward Market Entry, Finds DelveInsight | Outlook Therapeutics, Opthea, Sylentis, Boehringer Ingelheim, Molecular Partners, Sam Chun Dang Pharm, here
News-ID: 4394426 • Views: …
More Releases from DelveInsight
Ischemic Stroke Clinical Trial Pipeline Advances as 50+ Companies Develop 55+ Pi …
DelveInsight's "Ischemic Stroke - Pipeline Insight, 2026" report provides comprehensive insights about 50+ companies developing 55+ pipeline drugs in the Ischemic Stroke pipeline landscape. It covers the Ischemic Stroke pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.
Explore the latest breakthroughs in the Ischemic Stroke treatment landscape.…
Epidermolysis Bullosa Clinical Trial Pipeline Robust as 20+ Companies Advance 21 …
DelveInsight's "Epidermolysis Bullosa - Pipeline Insight, 2026" report provides comprehensive insights about 20+ companies developing 21+ pipeline drugs in the Epidermolysis Bullosa pipeline landscape. It covers the Epidermolysis Bullosa pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.
Explore the latest breakthroughs in the Epidermolysis Bullosa treatment landscape.…
Traumatic Brain Injury Clinical Trial Pipeline Accelerates as 20+ Pharma Compani …
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2026" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Traumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Spinal Implants Market Size Report 2032: Market Porter's Five Forces Analysis, M …
DelveInsight's Spinal Implants Market Insights Report 2032 provides the current and forecast market analysis, individual leading Spinal Implants Companies market shares, challenges, Spinal Implants Market Drivers, barriers, trends, and key market Spinal Implants companies in the market.
To read more about the latest highlights related to the Spinal Implants Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/spinal-implants-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Spinal…
More Releases for Wet
Wet Age-Related Macular Degeneration (Wet AMD) market is expected to reach USD 1 …
Wet age-related macular degeneration (Wet AMD) is a chronic, progressive eye disorder and one of the leading causes of severe vision loss in people over 60. Unlike the dry form of AMD, Wet AMD is characterized by the growth of abnormal blood vessels under the retina that leak fluid or blood, leading to rapid central vision loss. While Wet AMD accounts for only about 10-15% of all AMD cases, it…
Wet And Cold Appliance Market Size Analysis by Application, Type, and Region: Fo …
USA, New Jersey- According to Market Research Intellect, the global Wet And Cold Appliance market in the Internet, Communication and Technology category is projected to witness significant growth from 2025 to 2032. Market dynamics, technological advancements, and evolving consumer demand are expected to drive expansion during this period.
The wet and cold appliance market is expanding steadily, driven by changing consumer lifestyles, increasing urbanization, and rising demand for home automation. Appliances…
Semiconductor Electronic Wet Chemicals Market
Semiconductor Electronic Wet Chemicals Market Overview
Electronic wet chemicals are ultra-pure nature due to which they are extensively used in cleaning and etching application during semiconductor production and processing.
This report provides a deep insight into the global Semiconductor Electronic Wet Chemicals market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market…
Wet and Dry Vacuum Cleaner Market
The "Wet and Dry Vacuum Cleaner Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023.
Growing Demand and Growth Potential in the Global Wet and Dry Vacuum Cleaner Market, 2024-2031
Verified Market Research's most recent report, "Wet and Dry Vacuum Cleaner Market: Global Industry Trends, Share, Size,…
Wet Filtered Downdraught Workbench Market
Wet filtered downdraught workbench is the industry's leading solution for the collection of combustible metal dust which can safely removes combustible materials while complying with NFPA and OSHA combustible dust guidelines.
The global Wet Filtered Downdraught Workbench market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine…
Corn Wet-milling Market Corn Wet Milling Market Share, Size, Demand, Key Players …
Market Analysis and Insights of Global Corn Wet-milling Market
The corn wet-milling market is expected to witness market growth at a rate of 5.70% in the forecast period of 2022 to 2029. Data Bridge Market Research report on corn wet-milling market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market's growth. The growth in awareness globally is…
